A Brand New Network
for RAS-Targeted Therapies
Welcome to the RAS-Targeted Therapies Development: Searchlight network
Built by the RAS Drug Development community for the RAS Drug Development community
The once undruggable RAS family of proteins is no longer impossible to crack. But while the future looks bright, significant challenges remain.
Some of those challenges require us to focus on finding breakthroughs in isolation. But there are many other problems where we could save valuable time and resources by solving them together.
RAS-Targeted Therapies: Searchlight is a unique network of RAS specialists who engage in a year-round collective effort to solve shared discovery challenges for the benefit of our teams, companies, and patients.
Built by the RAS industry for the RAS industry, the network provides a continuous flow of timely insights and valuable experiences that will shape the RAS field. The goal of the network is simple, to help overcome shared discovery challenges, get to development faster, and map out a more robust clinical plan.
Join RAS-Targeted Therapies: Searchlight today to access vital new thinking, identify critical strategies, and avoid costly mistakes in RAS-targeted drug development,
Don’t miss out on the opportunity to be part of these critical conversations…
"Available therapies specifically designed for RAS mutant cancers."
"Finding the best disease models to replicate each drug target"
"Understanding which combinations therapies to use"
Join your peers today and be part of a global community of like-minded individuals
For more information on what’s included as part of the RAS-Targeted Therapies Development: Searchlight membership, please download the membership brochure.
Here’s what you’ll learn more about:
- The unique mission and purpose of the network
- What membership includes
- How the quarterly cornerstone meetings work
- How bespoke value delivery works
- How we deliver demonstrable value to you
- Annual member investment
The feedback from members speaks for itself…
Steve Kelsey, President – R&D, Revolution
“While of course we need to be sensitive to IP, it’s just not efficient for individual companies to continue to work in isolation, so it’s vital we pool experiences and I’m excited about where this might lead.”
Greg Friberg, Vice President Medical Affairs, Amgen
“This is such a great idea. Some will inevitably be defined by what they can’t share but there are definitely others out there who aren’t and I think this is a necessary conversation which has my support.”
To read more reviews about RAS-Targeted Therapies: Searchlight membership, visit our testimonials page and hear directly from our members about why they've joined.
Discover how we can provide you with demonstrable value…
Whitepaper outputs will amplify member positions to an audience of regulators, suppliers, partners and more
Access timely insights to allow faster access to the clinic and increase your chances of success once you get there
Plug into a collaborative network sharing the full range of non-competitive ways to overcome common challenges
Who qualifies for RAS-Targeted Therapies: Searchlight?
Strategic RAS-focused leaders
Member companies are represented by one internal champion who has strategic oversight over its RAS program
Motivated to share
Members will require a collaborative mindset, focused on what can be shared rather than being restricted by what can’t
In sight of the clinic
Members will be curated based on development stage (with those either in or close to reaching the clinic having priority)